| Enrolling By Invitation | TruGraf Liver Gene Expression Serial Test NCT06061341 | Washington University School of Medicine | — |
| Recruiting | Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome NCT06519162 | Chungnam National University Hospital | — |
| Completed | Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC) NCT05374200 | University of Alberta | N/A |
| Unknown | Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Ci NCT04956328 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 |
| Unknown | A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for NCT04933292 | Xiaoli Fan | Phase 4 |
| Completed | Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis NCT04604652 | HighTide Biopharma Pty Ltd | Phase 2 |
| Unknown | PBC Induced Fatigue Treated With Thiamine NCT04893993 | Henning Grønbæk | Phase 4 |
| Completed | Online Wellness Intervention for Primary Biliary Cholangitis (PBC) NCT04791527 | University of Alberta | N/A |
| Unknown | A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis NCT04751188 | Instituto Mexicano del Seguro Social | Phase 3 |
| Recruiting | Bezafibrate in Patients With Primary Biliary Cholangitis (PBC) NCT04514965 | University of Aarhus | — |
| Active Not Recruiting | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) NCT04526665 | Ipsen | Phase 3 |
| Unknown | A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) NCT04278820 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Completed | Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atr NCT04522869 | Vinmec Research Institute of Stem Cell and Gene Technology | Phase 1 / Phase 2 |
| Completed | Gut Microbes and Metabolic Group in Different PBC Patients for UDCA Response NCT03590886 | Sun Yat-sen University | — |
| Completed | Repeatability and Reproducibility of Quantitative MRCP NCT03809559 | Perspectum | — |
| Completed | Clinical Trial on the Effect of the Sublimated Mare Milk Supplement on Primary Biliary Cholangitis NCT03665519 | National Scientific Medical Center, Kazakhstan | N/A |
| Active Not Recruiting | Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) NCT03301506 | Gilead Sciences | Phase 3 |
| Unknown | Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis NCT03668145 | Xijing Hospital of Digestive Diseases | N/A |
| Completed | Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholan NCT03112681 | Zydus Therapeutics Inc. | Phase 2 |
| Completed | Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol NCT03226067 | Calliditas Therapeutics AB | Phase 2 |
| Completed | Repeatability and Reproducibility of Multiparametric MRI NCT03743272 | Perspectum | — |
| Unknown | Paternally Inherited Phenotypes in Cholestasis NCT03337074 | Guy's and St Thomas' NHS Foundation Trust | — |
| Completed | An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects NCT03082937 | Albireo | Phase 1 |
| Recruiting | Biobank for Cholestatic Liver Diseases. NCT03445585 | Mayo Clinic | — |
| Completed | Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of M NCT03489889 | University of Sao Paulo General Hospital | N/A |
| Completed | Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) NCT02955602 | Gilead Sciences | Phase 2 |
| Unknown | Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non- NCT02937012 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 3 |
| Recruiting | sCD163 in PBC Patients - Assessment of Treatment Response NCT02931513 | University of Aarhus | — |
| Active Not Recruiting | sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis NCT02924701 | University of Aarhus | — |
| Completed | Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT NCT03253276 | University of Aarhus | EARLY_Phase 1 |
| Completed | Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis NCT02823353 | Xijing Hospital of Digestive Diseases | Phase 3 |
| Unknown | Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid NCT02916641 | Xijing Hospital of Digestive Diseases | Phase 3 |
| Unknown | Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid NCT02823366 | Xijing Hospital of Digestive Diseases | Phase 3 |
| Withdrawn | Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response NCT02965911 | Beijing 302 Hospital | Phase 1 / Phase 2 |
| Unknown | Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis NCT02916290 | Xijing Hospital of Digestive Diseases | Phase 3 |
| Completed | The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland NCT02846896 | Fondazione Epatocentro Ticino | — |
| Completed | Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis NCT02557360 | Pomeranian Medical University Szczecin | Phase 4 |
| Completed | Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis NCT02659696 | Teikyo University | — |
| Completed | Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients NCT02477462 | University of California, Davis | — |
| Withdrawn | An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Bilia NCT02321306 | Mirum Pharmaceuticals, Inc. | Phase 2 |
| Unknown | Pilot Study of FFP104 Dose Escalation in PBC Subjects NCT02193360 | Fast Forward Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis NCT02078882 | Christopher Bowlus, MD | Phase 4 |
| Completed | Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis NCT02135536 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis NCT02026401 | NGM Biopharmaceuticals, Inc | Phase 2 |
| Completed | Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Bili NCT01865812 | Intercept Pharmaceuticals | Phase 2 |
| Completed | Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cir NCT01904058 | Mirum Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 NCT02963077 | Albireo | Phase 1 |
| Completed | Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT NCT01879735 | University of Aarhus | Phase 1 |
| Completed | B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis NCT02376335 | Newcastle-upon-Tyne Hospitals NHS Trust | Phase 2 |
| Terminated | Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis NCT01614405 | University of Alberta | N/A |
| Completed | Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis NCT01473524 | Intercept Pharmaceuticals | Phase 3 |
| Unknown | Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cir NCT01440309 | Robert Chunhua Zhao, MD, PhD | Phase 1 |
| Unknown | Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis NCT01662973 | Beijing 302 Hospital | Phase 1 / Phase 2 |
| Completed | High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis NCT01603199 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | N/A |
| Completed | A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inad NCT01389973 | Janssen Research & Development, LLC | Phase 2 |
| Withdrawn | Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis NCT01141296 | University of Miami | Phase 2 |
| Completed | Pentoxifylline for Primary Biliary Cirrhosis NCT01249092 | The Cleveland Clinic | Phase 2 |
| Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168 | Sanford Health | — |
| Completed | Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cir NCT01857284 | Beijing Friendship Hospital | Phase 3 |
| Completed | Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) NCT00943176 | Mayo Clinic | Phase 1 |
| Terminated | Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC) NCT00746486 | Dr. Falk Pharma GmbH | Phase 3 |
| Completed | Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis NCT01510860 | Dr. Falk Pharma GmbH | Phase 4 |
| Withdrawn | Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune NCT00587119 | Mayo Clinic | N/A |
| Completed | Use of Fenofibrate for Primary Biliary Cirrhosis NCT00575042 | University of Florida | Phase 2 |
| Completed | Initial Study of Rituximab to Treat Primary Biliary Cirrhosis NCT00364819 | University of California, Davis | Phase 1 / Phase 2 |
| Completed | Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis NCT00805805 | George Brewer | Phase 3 |
| Completed | Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis NCT00844402 | Medical University of Graz | Phase 3 |
| Withdrawn | Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis NCT00393185 | Richard Burt, MD | Phase 1 |
| Completed | Study of Combivir for Patients With Primary Biliary Cirrhosis NCT00490620 | University of Alberta | Phase 2 / Phase 3 |
| Completed | Moexipril for Primary Biliary Cirrhosis NCT00588302 | Mayo Clinic | Phase 2 |
| Completed | Genetic Epidemiology of Primary Biliary Cirrhosis (PBC) NCT01161953 | Mayo Clinic | — |
| Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity NCT03941184 | Mayo Clinic | — |
| Terminated | Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antib NCT01430429 | Light Chain Bioscience - Novimmune SA | Phase 2 |